Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Acute myeloid leukemia with 4q12 rearrangements does not involve pdgfra

Long Chen, Yani Lin, Hong Zhang et al. Nov 03, 2025 pp. 1692-1692 10.1182/blood-2025-1692

Abstract Background:Chromosome 4q12 rearrangements are recurrent molecular alterations in hematologic malignancies, and the most common onco...

HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription

William Ciurylo Nov 03, 2025 pp. 1309-1309 10.1182/blood-2025-1309

Abstract 'HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis’ publi...

Evaluation of the American society of hematology quality improvement training institute: Impact on learner quality improvement knowledge, confidence, and satisfaction

Michael Keng, Menaka Pai, Tanya Thomas et al. Nov 03, 2025 pp. 6426-6426 10.1182/blood-2025-6426

Abstract Background: The American Society of Hematology (ASH) Quality Improvement Training Institute (QITI) launched in March 2024 to build...

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang et al. Nov 03, 2025 pp. 3819-3819 10.1182/blood-2025-3819

Abstract Background: Polycythemia Vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by the JAK2 V617F mutation, characterized by...

CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia

Saubia Fathima, Lior Rokach, Muhammad Yousuf et al. Nov 03, 2025 pp. 3844-3844 10.1182/blood-2025-3844

Abstract Background Blast transformation (BT) occurs in approximately 15-30% of patients with chronic myelomonocytic leukemia (CMML) and rema...

Spatial transcriptomic analysis of chronic lymphocytic leukemia lymph nodes reveals tumor microenvironment evolution during disease progression

Maria Carmela Vegliante, Benedetta Apollonio, Antonella Bucci et al. Nov 03, 2025 pp. 3880-3880 10.1182/blood-2025-3880

Abstract Introduction . Chronic lymphocytic leukemia (CLL) cells bidirectionally interacts with the tumor microenvironment (TME). Leukemic ce...

Cancer specific risk and mortality due to autoimmune hemolytic anemia (AIHA) associated with immune checkpoint inhibitors (ICI)

Haris Sohail, Jennifer Collins, Amir Kamran Nov 03, 2025 pp. 4741-4741 10.1182/blood-2025-4741

Abstract Background Immune checkpoint inhibitors (ICI) are cornerstone of treatment of majority of the solid cancers wit...

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

Zhuoer Xie, Qianxing Mo, Sarah Buckley et al. Nov 03, 2025 pp. 3873-3873 10.1182/blood-2025-3873

Abstract Background and Significance: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with overlapping dysplastic...

A CRISPR screen in enucleated human red cells identifies CLIC3 and VAMP8 as critical regulators of terminal erythropoiesis

Marilou Tetard, Tianjian Lin, Nana Peterson et al. Nov 03, 2025 pp. 972-972 10.1182/blood-2025-972

Abstract During terminal erythroid differentiation, committed precursor cells proliferate and differentiate down the erythroid lineage, yiel...

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Kai Shen, Chenlu Yang, Jinrong Yang et al. Nov 03, 2025 pp. 7422-7422 10.1182/blood-2025-7422

Abstract Introduction: Chronic lymphocytic leukaemia (CLL), a hematologic malignancy of B cells, is one of the most freq...

CD5 positivity and aberrant P53 expression predict primary refractoriness to first-line pola-R-CHP in patients with diffuse large B-cell lymphoma

Xia Zhao, Zhihe Liu, Junqing Xu et al. Nov 03, 2025 pp. 1887-1887 10.1182/blood-2025-1887

Abstract Background: The Pola-R-CHP regimen has emerged as an effective initial treatment for patients with newly diagnosed diffuse large B-...

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Yamuna Kondapally, Julie Fortier, Antony Tin et al. Nov 03, 2025 pp. 2219-2219 10.1182/blood-2025-2219

Abstract Introduction Measurable residual disease (MRD) in bone marrow has become an important surrogate endpoint in multiple myeloma studie...

Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Hagop Kantarjian, Nicholas Short et al. Nov 03, 2025 pp. 1578-1578 10.1182/blood-2025-1578

Abstract Introduction: The outcome of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has dras...

Immunological biomarkers and TARC/CCL17 in myelodysplastic syndrome: Insights into immune microenvironment regulation

Fatma Zehra Yasar, Pinar Tiglioglu, Fergun Yilmaz et al. Nov 03, 2025 pp. 7359-7359 10.1182/blood-2025-7359

Abstract Background: Immune dysregulation is central to myelodysplastic syndrome (MDS) pathogenesis, with inflammatory cytokines and chemoki...

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

Wanying Liu, Jiaying Wu, Xi Ming et al. Nov 03, 2025 pp. 7245-7245 10.1182/blood-2025-7245

Abstract Abstract Background: Patients with primary breast lymphoma (PBL) who are refractory to initial therapy or who r...

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma

Xiujuan Huang, Yanping Ma, Zhenyu Li et al. Nov 03, 2025 pp. 7571-7571 10.1182/blood-2025-7571

Abstract Background Patients with relapsed/refractory multiple myeloma (RRMM) are prone to drug resistance after multiple lines of treatment...

Pharmacokinetic and pharmacodynamic characteristics of emicizumab in Chinese pediatric patients with hemophilia A: A retrospective single-center study

Qianqian Mao, Zhengping Li, Zhenping Chen et al. Nov 03, 2025 pp. 6614-6614 10.1182/blood-2025-6614

Abstract Background Emicizumab, a bispecific monoclonal antibody that mimics activated FVIII, is now the standard prophylaxis for hemophilia...

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma

Kate Manos, Melinda Burgess, Geoffrey Chong et al. Nov 03, 2025 pp. 3306-3306 10.1182/blood-2025-3306

Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) is clinically and biologically heterogenous. Though immune c...

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Ziyu Feng, Jia Chen, Haiping Dai et al. Nov 03, 2025 pp. 1674-1674 10.1182/blood-2025-1674

Abstract Background: Induction with cytarabine/anthracycline-based regimen (7+3 regimen) followed by consolidation with high-dose cytarabine...

Immature platelet fraction as a marker for romiplostim discontinuation in immune thrombocytopenia: Experience from cuenca, Ecuador

Héctor Chiang Wong, Patricio González Saldaña, Luis Renato Layedra Bardi Nov 03, 2025 pp. 1257-1257 10.1182/blood-2025-1257

Abstract Introduction: Romiplostim is a thrombopoietin receptor agonist used as a second-line treatment for primary immune thrombocytopenia...

Apoptotic rewiring via PI3K hyperactivation as a therapeutic strategy in B-cell malignancies

Stephen Martindale, Etienne Leveille, Jing Wang et al. Nov 03, 2025 pp. 437-437 10.1182/blood-2025-437

Abstract Background and Significance: PTEN is a critical negative regulator of PI3K/AKT signaling that dephosphorylates PI(3,4,5)P3 to PI(4,...

Adult acute myeloid leukaemia with DDX3X::MLLT10: A rare entity with significant unmet clinical needs

Jun Yen Ng, Arun SR, Maansi Joshi et al. Nov 03, 2025 pp. 7014-7014 10.1182/blood-2025-7014

Abstract Background DDX3X and MLLT10 genes are located on chromosomes X and 10, respectively. In a study of 2,080 children and young adults...

Outcomes in pediatric patients with HSCT-TMA treated with ravulizumab

Michelle Schoettler, David Bueno, Sonali Chaudhury et al. Nov 03, 2025 pp. 1052-1052 10.1182/blood-2025-1052

Abstract Background: Hematopoietic stem cell transplantation–associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening co...

Methionine promotes glycolysis and tumor progression in multiple myeloma by enhancing POU2AF1 expression via m⁶A modification

Chi Ma, Aoshuang Xu, Qun Li et al. Nov 03, 2025 pp. 5706-5706 10.1182/blood-2025-5706

Abstract INTRODUCTION: Multiple myeloma (MM), the second most prevalent hematologic malignancy, is characterized by the abnormal proliferati...

Locational patterns and ecological catalysts of cutaneous T-cell lymphoma: Insights from a Louisiana medical center (2019–2024)

Faradia Kernizan, Carole Bitar Nov 03, 2025 pp. 8018-8018 10.1182/blood-2025-8018

Abstract Background Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin, caused by malig...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page